PMID- 35331250
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220401
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 20
IP  - 1
DP  - 2022 Mar 24
TI  - Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal 
      cancer: a systematic review and meta-analysis.
PG  - 93
LID - 10.1186/s12957-022-02549-7 [doi]
LID - 93
AB  - BACKGROUND: Immunotherapy for colorectal cancer has developed rapidly in the past 
      decade. Many high-quality clinical trials examining the application of PD-1/PD-L1 
      inhibitors in patients with metastatic colorectal cancer (mCRC) have been 
      conducted in recent years. However, the clinical benefits, including the efficacy 
      and safety of these treatments against mCRC, remain controversial. Hence, we 
      conducted this meta-analysis on the clinical benefits of PD-1/PD-L1 inhibitors in 
      patients with mCRC. METHODS: We searched online databases including MEDLINE, 
      Embase, Cochrane Library, and Web of Science, from inception to January 4, 2021. 
      The outcomes related to efficacy and safety were extracted and analyzed. Subgroup 
      analyses were conducted according to the categories of dMMR-MSI-H (tumors with 
      mismatch repair deficiency and high levels of microsatellite instability) >/= 5% 
      vs. dMMR-MSI-H < 5%, monotherapy vs. combination therapy, PD-1 inhibitors vs. 
      PD-L1 inhibitors, and nivolumab vs. pembrolizumab. RESULTS: Fourteen studies 
      including 1129 subjects were included in our systematic review. The overall 
      complete response (CR), partial response (PR), stable disease (SD), and 
      progression of disease (PD) rates were 0.01 (95% CI 0.00-0.04), 0.04 (95% CI 
      0.05-0.26), 0.27 (95% CI 0.22-0.32), and 0.44 (95% CI 0.30-0.58), respectively. 
      The overall objective response rate (ORR) and disease control rate (DCR) were 
      0.16 (95%CI 0.06-0.31) and 0.50 (95%CI 0.35-0.65), respectively. The overall rate 
      of adverse events (AEs) and severe adverse responses (SAEs) were 0.84 (95% CI 
      0.72-0.92) and 0.30 (95% CI 0.20-0.41), respectively. The ORRs of the dMMR-MSI-H 
      >/= 5% and dMMR-MSI-H < 5% subgroups were 0.40 (95% CI 0.30-0.51) and 0.04 (95% CI 
      0.00-0.09), respectively. CONCLUSIONS: PD-1/PD-L1 inhibitors produced encouraging 
      clinical benefits including the response rate in the treatment of dMMR-MSI-H 
      mCRC. They actually have been influenced by the present state of mCRC therapy 
      including pMMR-MSI-L mCRC. Nevertheless, additional multi-center prospective 
      studies are still expected. TRIAL REGISTRATION: We have registered this study in 
      the International Prospective Register of Systematic Reviews (PROSPERO), and the 
      registration number is CRD42021249601 .
CI  - (c) 2022. The Author(s).
FAU - Zhang, Xiao
AU  - Zhang X
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical 
      University, 95 Yong-an Rd, Xi-Cheng District, Beijing, China.
FAU - Yang, Zhengyang
AU  - Yang Z
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical 
      University, 95 Yong-an Rd, Xi-Cheng District, Beijing, China.
FAU - An, Yongbo
AU  - An Y
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical 
      University, 95 Yong-an Rd, Xi-Cheng District, Beijing, China.
FAU - Liu, Yishan
AU  - Liu Y
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical 
      University, 95 Yong-an Rd, Xi-Cheng District, Beijing, China.
FAU - Wei, Qi
AU  - Wei Q
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical 
      University, 95 Yong-an Rd, Xi-Cheng District, Beijing, China.
FAU - Xu, Fengming
AU  - Xu F
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical 
      University, 95 Yong-an Rd, Xi-Cheng District, Beijing, China.
FAU - Yao, Hongwei
AU  - Yao H
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical 
      University, 95 Yong-an Rd, Xi-Cheng District, Beijing, China. 
      yaohongwei@ccmu.edu.cn.
FAU - Zhang, Zhongtao
AU  - Zhang Z
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical 
      University, 95 Yong-an Rd, Xi-Cheng District, Beijing, China. 
      zhangzht@ccmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220324
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - B7-H1 Antigen
MH  - *Colonic Neoplasms/drug therapy
MH  - *Colorectal Neoplasms/drug therapy/genetics
MH  - Humans
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - Programmed Cell Death 1 Receptor
MH  - Prospective Studies
PMC - PMC8944161
OTO - NOTNLM
OT  - Clinical efficacy
OT  - Colorectal neoplasms
OT  - Immune checkpoint inhibitors
OT  - Meta-analysis
COIS- The authors declare that they have no competing interests.
EDAT- 2022/03/26 06:00
MHDA- 2022/03/29 06:00
PMCR- 2022/03/24
CRDT- 2022/03/25 05:31
PHST- 2022/01/13 00:00 [received]
PHST- 2022/03/01 00:00 [accepted]
PHST- 2022/03/25 05:31 [entrez]
PHST- 2022/03/26 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2022/03/24 00:00 [pmc-release]
AID - 10.1186/s12957-022-02549-7 [pii]
AID - 2549 [pii]
AID - 10.1186/s12957-022-02549-7 [doi]
PST - epublish
SO  - World J Surg Oncol. 2022 Mar 24;20(1):93. doi: 10.1186/s12957-022-02549-7.